Effect of polyanion-resistance on HIV-1 infection

Virology

Volumn 325, Issue 2, 2004, Pages 389-398

  Bobardt, Michael D ^a   Armand Ugón, Mercedes ^b   Clotet, Imma ^b   Zhang, Zhe ^c   David, Guido ^c   Este, Jose A ^b   Gallay, Philippe A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

HIV 1; Polyanion; T cell

Indexed keywords

GLYCOPROTEIN GP 120; HEXADIMETHRINE BROMIDE; POLYANION; POLYCATION; PROTEOHEPARAN SULFATE;

ADHERENT CELL; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; T LYMPHOCYTE; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIGENS, CD4; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG RESISTANCE, VIRAL; HEPARAN SULFATE PROTEOGLYCANS; HEXADIMETHRINE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; POLYMERS; VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 3142540887     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.05.011     Document Type: Article

References (42)

1. Argyris E.G., Acheampong E., Nunnari G., Mukhtar M., Jon Williams K., Pomerantz R.J. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J. Virol. 77:2003;12140-12151
2. Baba M., Snoeck R., Pauwels R., De Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. 32:1988;1742-1745
3. Bagasra O., Whittle P., Heins B., Pomerantz R.J. Anti-human immunodeficiency virus type 1 activity of sulfated monosaccharides: comparison with sulfated polysaccharides and other polyions. J. Infect. Dis. 164:1991;1082-1090
4. Basmaciogullari S., Babcock G.J., Van Ryk D., Wojtowicz W., Sodroski J. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J. Virol. 76:2002;10791-10800
5. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:1999;729-777
6. Bobardt M.D., Saphire A.C., Hung H.C., Yu X., Van der Schueren B., Zhang Z., David G., Gallay P.A. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity. 18:2003;27-39
7. Bobardt M.D., Salmon P., Wang L., Esko J.D., Gabuzda D., Fiala M., Trono D., Van der Schueren B., David G., Gallay P.A. Contribution of proteoglycans to HIV-1 brain invasion. J. Virol. 78:2004;6567-6584
8. Callahan L.N., Phelan M., Mallinson M., Norcross M.A. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1991;1543-1550
9. Derdeyn C.A., Decker J.M., Sfakianos J.N., Zhang Z., O'Brien W.A., Ratner L., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:2001;8605-8614
10. de Vreese K., Kofler-Mongold V., Leutgeb C., Weber V., Vermeire K., Schacht S., Anne J., de Clercq E., Datema R., Werner G. The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. J. Virol. 70:1996;689-696
11. Dragic T., Trkola A., Lin S.W., Nagashima K.A., Kajumo F., Zhao L., Olson W.C., Wu L., Mackay C.R., Allaway G.P., Sakmar T.P., Moore J.P., Maddon P.J Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72:1998;279-285
12. Este J.A., Schols D., De Vreese K., Van Laethem K., Vandamme A.M., Desmyter J., De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:1997;98-104
13. Este J.A., Cabrera C., Schols D., Cherepanov P., Gutierrez A., Witvrouw M., Pannecouque C., Debyser Z., Rando R.F., Clotet B., Desmyter J., De Clercq E. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 53:1998;340-345
14. Farzan M., Choe H., Vaca L., Martin K., Sun Y., Desjardins E., Ruffing N., Wu L., Wyatt R., Gerard N., Gerard C., Sodroski J. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J. Virol. 72:1998;1160-1164
15. Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M., Gerard N.P., Gerard C., Sodroski J., Choe H. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 96:1999;667-676
16. Guibinga G.H., Miyanohara A., Esko J.D., Friedmann T. Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Molec. Ther. 5:2002;538-546
17. Harrop H.A., Coombe D.R., Rider C.C. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS. 8:1994;183-192
18. Hatse S., Princen K., Gerlach L.O., Bridger G., Henson G., De Clercq E., Schwartz T.W., Schols D. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60:2001;164-173
19. Ito M., Baba M., Sato A., Pauwels R., De Clercq E., Shigeta S. Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res. 7:1987;361-367
20. Kwong P.D., Wyatt R., Sattentau Q.J., Sodroski J., Hendrickson W.A. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74:2000;1961-1972
21. Liu N.Q., Lossinsky A.S., Popik W., Li X., Gujuluva C., Kriederman B., Roberts J., Pushkarsky T., Bukrinsky M., Witte M., Weinand M., Fiala M. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J. Virol. 76:2002;6689-6700
22. Mbemba E., Chams V., Gluckman J.C., Klatzmann D., Gattegno L. Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate. Biochim. Biophys. Acta. 1138:1992;62-67
23. Meylan P.R., Kornbluth R.S., Zbinden I., Richman D.D. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds. Antimicrob. Agents Chemother. 38:1994;2910-2916
24. Mitsuya H., Looney D.J., Kuno S., Ueno R., Wong-Staal F., Broder S. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science. 240:1988;646-649
25. Mondor I., Ugolini S., Sattentau Q.J. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J. Virol. 72:1998;3623-3634
26. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., Thorstensson R., Fenyo E.M., Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:1999;2343-2349
27. Moulard M., Lortat-Jacob H., Mondor I., Roca G., Wyatt R., Sodroski J., Zhao L., Olson W., Kwong P.D., Sattentau Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:2000;1948-1960
28. O'Doherty U., Swiggard W.J., Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74:2000;10074-10080
29. Ohshiro Y., Murakami T., Matsuda K., Nishioka K., Yoshida K., Yamamoto N. Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection. Microbiol. Immunol. 40:1996;827-835
30. Okada T., Patterson B.K., Gurney M.E. Inhibition of anti-V3 domain antibody binding to human immunodeficiency virus type-1-infected cells by sulfated polysaccharides. Biochem. Biophys. Res. Commun. 209:1995;850-858
31. Patel M., Yanagishita M., Roderiquez G., Bou-Habib D.C., Oravecz T., Hascall V.C., Norcross M.A. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retroviruses. 9:1993;167-174
32. Pohlmann S., Leslie G.J., Edwards T.G., Macfarlan T., Reeves J.D., Hiebenthal-Millow K., Kirchhoff F., Baribaud F., Doms R.W. DC-SIGN interactions with human immunodeficiency virus: virus binding and transfer are dissociable functions. J. Virol. 75:2001;10523-10526
33. Rabut G.E.E., Konner J.A., Kajumo F., Moore J.P., Dragic T. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J. Virol. 72:1998;3464-3468
34. Roderiquez G., Oravecz T., Yanagishita M., Bou-Habib D.C., Mostowski H., Norcross M.A. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J. Virol. 69:1995;2233-2239
35. Saphire A.C., Bobardt M.D., Zhang Z., David G., Gallay P.A. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J. Virol. 75:2001;9187-9200
36. Schols D., Pauwels R., Desmyter J., De Clercq E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology. 175:1990;556-561
37. Ueno R., Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine. Lancet. 1:1987;1379
38. Wang W.K., Dudek T., Zhao Y.J., Brumblay H.G., Essex M., Lee T.H. CCR5 coreceptor utilization involves a highly conserved arginine residue of HIV type 1 gp120. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5740-5745
39. Wang W.K., Dudek T., Essex M., Lee T.H. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4558-4562
40. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:2002;1896-1905
41. Xu Y., Zhang X., Matsuoka M., Hattori T. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 487:2000;185-188
42. Zhang Y.J., Hatziioannou T., Zang T., Braaten D., Luban J., Goff S.P., Bieniasz P.D. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 76:2002;6332-6343